Maravai LifeSciences Reports 39.7% Revenue Decline in Q3 2025

Maravai LifeSciences Holdings, Inc. reported a significant decline in financial performance for the third quarter of 2025, with total revenue of $41.6 million, down 39.7% from $69.0 million in the same period last year. The company's Nucleic Acid Production segment, which has been a key revenue driver, saw a 52.9% decrease in revenue, falling from $53.8 million to $25.4 million. This decline was attributed primarily to the absence of high-volume CleanCap orders for commercial vaccine programs, which had previously contributed substantially to revenue. In contrast, the Biologics Safety Testing segment experienced a modest increase in revenue, rising 7.2% to $16.3 million.

For the nine months ending September 30, 2025, Maravai's total revenue was $135.9 million, a decrease of 32.9% compared to $202.6 million in the same period of 2024. The Nucleic Acid Production segment's revenue dropped 44.8%, while the Biologics Safety Testing segment saw a 5.2% increase. The overall decline in revenue was largely due to the lack of recurring high-volume CleanCap sales, which had previously accounted for a significant portion of the company's income.

Maravai's operating expenses for the third quarter of 2025 totaled $46.7 million, a substantial reduction from $197.8 million in the prior year, primarily due to a goodwill impairment charge of $154.2 million recorded in Q3 2024. The company also implemented a corporate realignment plan in August 2025, resulting in a workforce reduction of approximately 25%, which is expected to lower annualized expenses by over $50 million. Restructuring costs associated with this plan amounted to $7.4 million for the quarter.

The company reported a net loss of $45.1 million for the third quarter of 2025, a significant improvement from the net loss of $172.5 million in the same quarter of 2024. The net loss attributable to Maravai LifeSciences Holdings, Inc. was $25.6 million, compared to $97.1 million in the prior year. For the nine-month period, the net loss was $167.7 million, down from $213.6 million in 2024. The improvement in net loss was attributed to reduced operating expenses and the absence of significant goodwill impairment charges.

Looking ahead, Maravai anticipates continued challenges due to the absence of high-volume CleanCap sales and a general contraction in economic activity, particularly in Asia. The company is focused on expanding its customer base and enhancing its product offerings through strategic acquisitions, including the recent purchases of Molecular Assemblies and Officinae Bio. Despite the current financial pressures, Maravai aims to leverage its existing cash reserves and credit facilities to support ongoing operations and strategic initiatives.